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Background: Inhaled antibiotics (ABs) are recommended for use in the therapy of chronic 
Pseudomonas aeruginosa infection in patients with cystic fibrosis (CF). The aim of this sys-
tematic literature review was to identify level of adherence to inhaled ABs and to determine 
predictors and consequences of nonadherence in CF.
Methods: A systematic literature search of English-language articles was conducted in April 2015 
using Medline and Embase. No publication date limit was applied. The literature screening was 
conducted by two independent reviewers. All of the included studies were assessed for quality.
Results: The search yielded 193 publications, of which ten met the inclusion criteria and 
underwent data extraction. Seven studies focused on inhaled tobramycin, one on inhaled 
colistimethate, one on inhaled levofloxacin, and one on inhaled aztreonam lysine. Medication 
adherence to inhaled ABs was analyzed by pharmacy refill history, daily phone diary, parent 
and child self-reports, vials counting, or electronic monitoring. In randomized controlled trials 
(n=3), proportion of adherent patients (.75%–80% of required doses taken) ranged from 86% 
to 97%; in prospective cohort studies (n=3), adherence rates ranged between 36% and 92%, and 
in retrospective studies (n=4) it ranged between 60% and 70%. The adherence to inhaled ABs 
in CF was found to be associated with the complexity of treatment, time of drug administration, 
age of patients, treatment burden (adverse events, taste), and patient satisfaction.
Conclusion: The high diversity of adherence data was because of the different study designs 
(randomized controlled trials vs real-world studies) and the lack of a commonly accepted con-
sensus on the definition of adherence in the reviewed articles. Routine adherence monitoring 
during CF care, discussing the possible reasons of suboptimal adherence with the patient, and 
changing treatment regimens on the basis of patient burden can individualize CF therapy for 
patients and may improve the level of adherence.
Keywords: cystic fibrosis, antibiotics, adherence, compliance, Pseudomonas aeruginosa
Introduction
Cystic fibrosis (CF) is an inherited disease that affects particularly the lungs, pancreas, 
hepatobiliar system, reproductive tract, and sweat glands.1,2 It is caused by mutations 
in the gene encoding the CF transmembrane conductance regulator protein.1,2
Chronic infection with Pseudomonas aeruginosa (PA) impacts the progress of 
lung disease, which determines the life expectancy in CF. PA is one of the most 
common gram-negative bacteria causing acute exacerbation and progress of the lung 
disease in CF.3 In the management of lung infection with PA, inhaled antibiotic (AB) 
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therapy is recommended as maintenance therapy.4 Aerosol 
delivery of ABs yields high concentration directly to the 
airways, where the bacterium persists while minimizing 
systemic exposure and toxicity.5–7 Colistimethate inhalation 
has been widely used in Europe, while current CF guidelines 
recommend chronic use of tobramycin inhalation solution 
(TIS) in the USA to improve lung function and to decrease 
exacerbations in chronic PA infection.8 Use of inhaled aztre-
onam was approved by the US Food and Drug Administration 
in December 2009, and efficacy of inhaled levofloxacin has 
been studied in a clinical Phase III trial for chronic PA infec-
tion in CF patients.9,10
Medication adherence (compliance) “refers to the act of 
conforming to the recommendations made by the provider 
with respect of timing, dosage, and frequency of medication 
taking”.11 In chronic diseases, such as in CF, medication 
nonadherence poses a significant barrier to optimal disease 
management. The daily therapy of CF, including chest 
physiotherapy, numerous oral and inhaled medications, 
nutritional supplements, and vitamins, involves a complex 
and time-consuming regimen for the patient,12 which may 
be a significant predictor of nonadherence. In CF, previ-
ous studies reported somewhat higher adherence than for 
other chronic diseases (eg, asthma and allergic rhinitis).12–15 
However, adherence is therapy-specific, and adherence rates 
may vary widely between different CF-related therapies. As 
it was identified in a cross-sectional study, higher treatment 
adherence to both respiratory (62%) and digestive treatment 
(88%), and lower adherence to physiotherapy (41%) and 
nutritional supplements (59%) were observed.16
Although many studies evaluated adherence to CF-related 
medications, only few of those investigated adherence to 
inhaled ABs.12,13,17 Nevertheless, evidence on prevalence 
and predictors of nonadherence to inhaled ABs would be 
highly valuable to the development of effective adherence-
enhancing interventions and to improve disease management 
of CF patients with chronic PA infection. Therefore, the aim 
of this systemic review was to identify level of adherence to 
inhaled ABs for chronic PA infection in CF and to determine 
the possible predictors and consequences of nonadherence 
on the basis of the existing publications. To our knowledge, 
no systematic review encompassing this topic has been 
published to date.
Materials and methods
A systematic literature search of English-language articles 
was conducted in April 2015 using Medline and Embase 
(via Scopus) with the following search terms: (adheren* 
OR persisten* OR complian*) AND (“cystic fibrosis” OR 
mucoviscidosis) AND (“Pseudomonas aeruginosa”) AND 
(antibiotic*). No publication date limits were defined. The 
search results were processed in two steps: first, the titles 
and abstracts were screened; next, all the full text of all the 
potentially relevant articles were analyzed. The references 
of the included articles were screened for additional eligible 
studies. The literature screening was conducted by two inde-
pendent reviewers; disagreements between reviewers were 
resolved by consensus.
The reasons for exclusion in both steps were the follow-
ing: 1) the article reported no new evidence (ie, editorial, 
letter, case report, or review), 2) the article was a case study, 
3) the article was not related to CF, and 4) the article had not 
assessed adherence to inhaled ABs for the treatment of chronic 
PA infection in CF. This review included only publications 
in which data on adherence to inhaled ABs were clearly 
separated from adherence data of other medications.
The data extraction was limited to findings relevant to the 
research topic. The following information was extracted from 
each included study: 1) the first author and year of publica-
tion, 2) the country, 3) the study design, 4) the study year, 
5) study exclusion and inclusion criteria, 6) the study popula-
tion characteristics, 7) the medication therapy, 8) the method 
of measuring and defining adherence, 9) adherence data, and 
10) predictors and consequences of nonadherence to inhaled 
ABs in CF. In case of studies in which adherence rates were 
presented graphically only, WebPlotDigitizer 3.8 was used to 
extract numerical data accurately out of figures. The scope of 
this review was to give a systematic overview on the adher-
ence to inhaled ABs in CF; therefore, results of adherence 
measures that were not applied to assess adherence to inhaled 
ABs were not abstracted from the included studies.
For the quality assessment of the included studies, the 
strengthening the reporting of observational studies in epide-
miology (STROBE) checklist18 was used. All the studies were 
independently assessed by two review authors; disagreements 
were resolved by consensus. The results of the quality assess-
ment were summarized as the percentage of the fulfilled 
criteria for each study (criteria that were not applicable to a 
study were excluded from the quality assessment), ranging 
from 0% (none of the applicable STROBE criteria fulfilled) 
to 100% (all applicable STROBE criteria fulfilled).
Results
The literature search resulted in 188 hits, and five additional 
records were identified through hand search of the references 
of relevant articles. The screening of the titles and abstracts 
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identified 17 potentially eligible studies. After the review of 
the relevant full texts, ten studies were finally included in the 
systematic review. The flow diagram of the systematic litera-
ture review process, based on the Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses (PRISMA)19 
template, is presented in Figure 1.
Three studies were randomized controlled trials 
(RCTs),20–22 three were prospective cohort studies,23–25 and 
four retrospective studies26–29 were also included. The popu-
lation size varied between 2828 and 83229 subjects, with a 
mean age of 9.128 to 28.720 years. Seven studies focused on 
measuring adherence to inhaled tobramycin,21–24,26,27,29 one on 
inhaled colistimethate,28 one on inhaled levofloxacin,20 and 
one on inhaled aztreonam lysine.25 The general characteristics 
of the reviewed studies are summarized in Table 1.
Medication adherence to inhaled ABs was analyzed 
by pharmacy refill history (30%),26,27,29 daily phone diary 
(10%),24 parent and/or child self-reports (20%),23,24 vials 
counting (30%),20,22,25 or electronic monitoring (10%).28 
Regnault et al21 were the only authors who did not describe 
the method for measuring adherence, while Modi et al24 and 
Oermann et al25 did not report how adherence was defined 
in their studies. Six studies20–23,26,29 determined adherence as 
categorical variable only, five studies24,25,27,28 as continuous 
only, and one study as both.21 Measurement methods, results, 
and predictors/consequences of adherence to inhaled ABs 
are presented in Table 1.
Except for the studies conducted by Eakin et al27 and 
Modi et al,24 most studies assessed adherence to inhaled ABs 
only and did not evaluate adherence to other medications 
simultaneously (Table 2).
The included studies fulfilled the STROBE criteria 
between 52%28 and 73%.21,29 Details of the quality assess-
ment are provided in Table S1. The majority of the studies 
described their scope, study design, settings, participants, 
variables, measurements, and main results adequately. All 
but one28 of the reviewed studies described their statisti-
cal methods in detail; however, none of them undertook a 
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Figure 1 The flow diagram of the systematic literature review process.
Abbreviation: CF, cystic fibrosis.
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Table 1 General characteristics and adherence to inhaled antibiotics results of the included studies
Study characteristics Randomized controlled trials Real-world studies
Prospective cohort studies Retrospective studies
Geller et al20 Ramsey et al22 Regnault et al21 Harrison et al23 Modi et al24 Oermann et al25 Briesacher et al26 Eakin et al27 McNamara et al28 Wertz et al29
Study length 28 daysa 24 weeks 24 weeks 12 months 3 months 18 months 12 months 12 months 12 months 12 months
No of subjects, total  
(on inhaled ABs)
151 (114) 520 (258) 454 (454) 78 (TiP: 51, TiS: 78) 37 (10) 274 (BiD: 89, TiD: 189) 804 (804) 95 (65) 28 (28) 832 (388)
Age, years 28.7 (9.0)b •	 Tobramycin group: 
20.8 (9.5)b
•	 Placebo group: 
20.6 (10.0)b
25.6 (10.8)b 26.3 (16–56)c 10.1 (2.5)b 28.5 (12.5)b ,6: 13.2%
6–10: 12.2%
11–17: 31.5%
18–25: 22.0%
$26: 21.1%
20.9 (11.9)b 9.1 (3–15)d TiS user group: 19e
Nonuser group: 30e
Male, % 56.3 •	 Tobramycin group: 
58
•	 Placebo group: 50
56.2 59 51 55.1 52.7 48.9 57 TiS user group: 52e
Nonuser group: 46e
Fev1, % predicted 52.3 (15.3)
b •	 Tobramycin group: 
49.9 (15.5)b
•	 Placebo group: 
51.2 (16.8)b
52.8 (14.5)b 63.5f 79.6 (20.8)b 55.6 (11.6)b NR 80.1 (24.8)b 75 (54–99)c NR
inhaled ABs inhaled 
levofloxacin
inhaled tobramycin TiP, TiS TiP, TiS inhaled tobramycin inhaled aztreonam lysine 
(BiD, TiD)
TiS inhaled tobramycin inhaled colistimethate TiS
Adherence
Measurement vials counting vials counting NR Self-report adherence Parent/child self-report, 
daily phone diary
vials counting Pharmacy refill records Pharmacy refill records electronic monitoring Pharmacy refill records
variable type Categorical Categorical Continuous, categorical Categorical Continuous Continuous Categorical Continuous Continuous Categorical
Definition Adherent 
patients: $80% 
of the required 
doses taken
Adherent patients: 
$75% of the ampoule 
dispensed
•	 Adherence: % of doses taken
•	 Adherent patients: $80% of 
the required doses taken
•	 excellent: .80% 
adherence
•	 Moderate: 50%–80% 
adherence
•	 Poor: ,50% 
adherence
NR NR •	 High: $4 cycles per  
12 monthsg
•	 Medium: .2 to ,4 
cycles per 12 monthsg
•	 Low: #2 cycles per  
12 monthsg
MPR: defined as the sum 
of all days of medication 
supply received, divided 
by the number of days the 
medication was prescribed 
for chronic use during the 
study period
The number of treatments 
taken divided by 
numbers of prescribed 
treatments ×100%
•	 High: .4 fills per  
12 months
•	 Medium: 2–3 fills per  
12 months
•	 Low: 1 fill per 12 months
Results, %/mean 
(SD) %h
% of adherent 
subjects: 
92.3%–97.3%
% of adherent 
subjects: 88%
•	 Adherence:
	 Cycle 1: 96.5 (10)%b,g
	 Cycle 2: 93.9 (15)%b,g
	 Cycle 3: 93.6 (14.5)%b,g
•	 % of adherent subjects:
	 Cycle 1: 93.4%g
	 Cycle 2: 88.1%g
	 Cycle 3: 86.4%g
•	 TiS at baseline:
	 excellent: 44.9%
	 Moderate: 30.6%
	 Poor: 24.5%
•	 TiP at 12-month:
	 excellent: 77.5%
	 Moderate: 17.5%
	 Poor: 5.0%
•	 Parent self-report: 
85.0 (33.7)%b
•	 Child self-report: 
83.3 (25.8)%b
•	 Diary: 36.1 (35.6)%b
•	 BiD: 92%
•	 TiD: 88%
•	 High: 7%
•	 Medium: 22%
•	 Low: 71%
MPR: 65%i •	 Adherence at 6 months: 
64 (35)%b
•	 Overall monthly 
adherence at 12 months: 
60%–70%
•	 High: 29.64%
•	 Medium: 34.54%
•	 Low: 35.82%
Predictors/
consequences
NR NR Higher patient satisfaction and 
lower perceived impact of 
side effects were found to be 
statistically significantly associated 
with better adherence
Adherence increased 
after transition from 
TiS to TiP
NR •	 Dosing regimen was not 
statistically significantly 
associated with adherence
•	 CFQ-R scores were 
comparable between BiD 
and TiD groups
•	 High adherence was 
significantly associated 
with a decreased risk 
of hospitalization, 
but inpatient costs 
were similar between 
the three adherence 
groups
•	 Outpatient costs 
were lower in high 
adherence groupj
•	 Drug costs were higher 
among high usersj
•	 Adherence was not 
correlated with 
number of medications 
prescribed
•	 No statistically 
significantly difference 
in age was found in 
adherence
•	 Adherence to inhaled 
ABs was not associated 
with the occurrence of 
pulmonary exacerbation, 
and change in Fev1% 
predicted slope
•	 evening adherence (75%) 
was significantly better 
than morning adherence 
(58%)
•	 Tendency for better 
overall adherence in 
children ,12 years (71%) 
than in teenagers (50%)j
•	 Changing the treatment 
regimens from twice daily 
to once daily improved 
adherence significantly (in 
the month pre- and post-
change from 26% to 54%)
•	 CF-related medication 
use was generally greater 
for the high adherence 
group compared with 
the medium and low 
adherence groups 
(P,0.0001)
•	 increase in adherence 
was associated with 
decreased health care 
resource utilization, 
increased drug costs, and 
decreased inpatient costs 
(P,0.05)
Notes: aTreatment period; bmean (SD); cmedian (range); dmean (range); emean; fmedian; gone cycle: 28 days on therapy followed by 28 days off therapy; honly adherence 
results for inhaled ABs are presented; iadherence rate was presented graphically only; jdifference was not assessed with statistical methods.
Abbreviations: ABs, antibiotics; Fev1, forced expiratory volume in 1 second; BID, two times daily; CF, cystic fibrosis; CFQ-R, cystic fibrosis questionnaire-revised; TID, 
three times daily; NR, not reported; MPR, medication possession ratio; SD, standard deviation; TiP, tobramycin inhalation powder; TiS, tobramycin inhalation solution.
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Table 1 General characteristics and adherence to inhaled antibiotics results of the included studies
Study characteristics Randomized controlled trials Real-world studies
Prospective cohort studies Retrospective studies
Geller et al20 Ramsey et al22 Regnault et al21 Harrison et al23 Modi et al24 Oermann et al25 Briesacher et al26 Eakin et al27 McNamara et al28 Wertz et al29
Study length 28 daysa 24 weeks 24 weeks 12 months 3 months 18 months 12 months 12 months 12 months 12 months
No of subjects, total  
(on inhaled ABs)
151 (114) 520 (258) 454 (454) 78 (TiP: 51, TiS: 78) 37 (10) 274 (BiD: 89, TiD: 189) 804 (804) 95 (65) 28 (28) 832 (388)
Age, years 28.7 (9.0)b •	 Tobramycin group: 
20.8 (9.5)b
•	 Placebo group: 
20.6 (10.0)b
25.6 (10.8)b 26.3 (16–56)c 10.1 (2.5)b 28.5 (12.5)b ,6: 13.2%
6–10: 12.2%
11–17: 31.5%
18–25: 22.0%
$26: 21.1%
20.9 (11.9)b 9.1 (3–15)d TiS user group: 19e
Nonuser group: 30e
Male, % 56.3 •	 Tobramycin group: 
58
•	 Placebo group: 50
56.2 59 51 55.1 52.7 48.9 57 TiS user group: 52e
Nonuser group: 46e
Fev1, % predicted 52.3 (15.3)
b •	 Tobramycin group: 
49.9 (15.5)b
•	 Placebo group: 
51.2 (16.8)b
52.8 (14.5)b 63.5f 79.6 (20.8)b 55.6 (11.6)b NR 80.1 (24.8)b 75 (54–99)c NR
inhaled ABs inhaled 
levofloxacin
inhaled tobramycin TiP, TiS TiP, TiS inhaled tobramycin inhaled aztreonam lysine 
(BiD, TiD)
TiS inhaled tobramycin inhaled colistimethate TiS
Adherence
Measurement vials counting vials counting NR Self-report adherence Parent/child self-report, 
daily phone diary
vials counting Pharmacy refill records Pharmacy refill records electronic monitoring Pharmacy refill records
variable type Categorical Categorical Continuous, categorical Categorical Continuous Continuous Categorical Continuous Continuous Categorical
Definition Adherent 
patients: $80% 
of the required 
doses taken
Adherent patients: 
$75% of the ampoule 
dispensed
•	 Adherence: % of doses taken
•	 Adherent patients: $80% of 
the required doses taken
•	 excellent: .80% 
adherence
•	 Moderate: 50%–80% 
adherence
•	 Poor: ,50% 
adherence
NR NR •	 High: $4 cycles per  
12 monthsg
•	 Medium: .2 to ,4 
cycles per 12 monthsg
•	 Low: #2 cycles per  
12 monthsg
MPR: defined as the sum 
of all days of medication 
supply received, divided 
by the number of days the 
medication was prescribed 
for chronic use during the 
study period
The number of treatments 
taken divided by 
numbers of prescribed 
treatments ×100%
•	 High: .4 fills per  
12 months
•	 Medium: 2–3 fills per  
12 months
•	 Low: 1 fill per 12 months
Results, %/mean 
(SD) %h
% of adherent 
subjects: 
92.3%–97.3%
% of adherent 
subjects: 88%
•	 Adherence:
	 Cycle 1: 96.5 (10)%b,g
	 Cycle 2: 93.9 (15)%b,g
	 Cycle 3: 93.6 (14.5)%b,g
•	 % of adherent subjects:
	 Cycle 1: 93.4%g
	 Cycle 2: 88.1%g
	 Cycle 3: 86.4%g
•	 TiS at baseline:
	 excellent: 44.9%
	 Moderate: 30.6%
	 Poor: 24.5%
•	 TiP at 12-month:
	 excellent: 77.5%
	 Moderate: 17.5%
	 Poor: 5.0%
•	 Parent self-report: 
85.0 (33.7)%b
•	 Child self-report: 
83.3 (25.8)%b
•	 Diary: 36.1 (35.6)%b
•	 BiD: 92%
•	 TiD: 88%
•	 High: 7%
•	 Medium: 22%
•	 Low: 71%
MPR: 65%i •	 Adherence at 6 months: 
64 (35)%b
•	 Overall monthly 
adherence at 12 months: 
60%–70%
•	 High: 29.64%
•	 Medium: 34.54%
•	 Low: 35.82%
Predictors/
consequences
NR NR Higher patient satisfaction and 
lower perceived impact of 
side effects were found to be 
statistically significantly associated 
with better adherence
Adherence increased 
after transition from 
TiS to TiP
NR •	 Dosing regimen was not 
statistically significantly 
associated with adherence
•	 CFQ-R scores were 
comparable between BiD 
and TiD groups
•	 High adherence was 
significantly associated 
with a decreased risk 
of hospitalization, 
but inpatient costs 
were similar between 
the three adherence 
groups
•	 Outpatient costs 
were lower in high 
adherence groupj
•	 Drug costs were higher 
among high usersj
•	 Adherence was not 
correlated with 
number of medications 
prescribed
•	 No statistically 
significantly difference 
in age was found in 
adherence
•	 Adherence to inhaled 
ABs was not associated 
with the occurrence of 
pulmonary exacerbation, 
and change in Fev1% 
predicted slope
•	 evening adherence (75%) 
was significantly better 
than morning adherence 
(58%)
•	 Tendency for better 
overall adherence in 
children ,12 years (71%) 
than in teenagers (50%)j
•	 Changing the treatment 
regimens from twice daily 
to once daily improved 
adherence significantly (in 
the month pre- and post-
change from 26% to 54%)
•	 CF-related medication 
use was generally greater 
for the high adherence 
group compared with 
the medium and low 
adherence groups 
(P,0.0001)
•	 increase in adherence 
was associated with 
decreased health care 
resource utilization, 
increased drug costs, and 
decreased inpatient costs 
(P,0.05)
Notes: aTreatment period; bmean (SD); cmedian (range); dmean (range); emean; fmedian; gone cycle: 28 days on therapy followed by 28 days off therapy; honly adherence 
results for inhaled ABs are presented; iadherence rate was presented graphically only; jdifference was not assessed with statistical methods.
Abbreviations: ABs, antibiotics; Fev1, forced expiratory volume in 1 second; BID, two times daily; CF, cystic fibrosis; CFQ-R, cystic fibrosis questionnaire-revised; TID, 
three times daily; NR, not reported; MPR, medication possession ratio; SD, standard deviation; TiP, tobramycin inhalation powder; TiS, tobramycin inhalation solution.
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sensitivity analysis to examine the robustness of the results. 
Furthermore, no study provided information on missing data 
and how they dealt with the same.
Discussion
Ten studies were identified and included in this systematic 
review.20–29 The majority of the studies focused on measur-
ing adherence to inhaled tobramycin (n=7).21–26,29 To our 
knowledge, this is the first systematic review of the adherence 
to inhaled ABs in CF. The results from the present study 
contribute to understanding the current status of adherence 
to inhaled ABs and for planning future research that can add 
to the global picture of adherence in CF.
Methodological issues: randomized 
controlled trials vs real-world studies
Most of the included publications were real-world studies 
(n=7)23–29 contrary to RCTs (n=3).20–22 From the viewpoint 
of health care professionals, real-world studies provide more 
reliable information about medication adherence in contrast 
with RCTs, which may overestimate adherence. As RCTs 
are mainly designed to assess safety and efficacy of phar-
maceuticals, the study design emphasizes internal validity 
over generalizability. In these studies, because of protocol 
requirements, the data may not be applicable to the more 
heterogeneous patient group encountered in actual clinical 
practice. Effectiveness studies (eg, prospective cohort studies 
and retrospective studies), where treatment and/or disease 
management is studied under real-world conditions (eg, in 
unselected populations; patients are under routine care, tak-
ing open-label treatment, with no additional visits), remedy 
some of these limitations. This issue is especially relevant 
in case of adherence data. In RCTs, usually better treatment 
adherence is obtained due to the continuous, obligatory con-
trol visits or measurement of serum drug levels. Moreover, 
patients sometimes feel that they are in favored situation, 
because they are eligible to take part in the study and use a 
novel, not launched medication in CF. In addition, between 
regular visits, phone calls also remind patients to the use/
administration of the drug, or they are asked about their 
experiences related to the new drug.
In the included RCTs,20–22 the proportion of adherent 
patients (.75%–80% of required doses taken) ranged 
between 86.4% (inhaled tobramycin, measurement method 
was not reported)21 and 97.3% (inhaled levofloxacin, mea-
sured by vials counting).20 In contrast, in the prospective 
cohort study conducted by Harrison et al,23 only 44.9% of 
patients reported greater than 80% adherence to TIS and 
77.5% to tobramycin inhalation powder (TIP) (measured 
by patient self-report). In the included retrospective stud-
ies, the proportion of highly adherent patients (.4 fills per 
12 months) was found to be in the range of 7% (inhaled 
tobramycin, measured by pharmacy refill records)26 to 29.6% 
(inhaled tobramycin, measured by pharmacy refill records)29 
(Table 1).
Adherence rates to inhaled antibiotics
Determining an overall rate for adherence to inhaled ABs 
in CF was difficult because different adherence definitions 
and measurement methods were applied in the reviewed 
studies; furthermore, two of the included studies24,25 did 
not declare a clear definition for adherence. In prospec-
tive cohort studies, adherence rates ranged between 36% 
(inhaled tobramycin, measured by daily phone diary)24 and 
92% (inhaled aztreonam, measured by vials counting),25 and 
in retrospective studies it ranged between 60% and 70% 
(inhaled colistimethate, measured by electronic monitoring)28 
(Table 1). Adherence to inhaled ABs did not differ signifi-
cantly from adherence rates to other CF-related medications 
(Table 2).27
Predictors of adherence
In the reviewed studies, adherence to inhaled ABs was 
found to be associated with the age of patients, patient’s 
Table 2 Comparison of adherence to inhaled antibiotics and other medications in patients with cystic fibrosis
Adherence measurements Inhaled 
tobramycin
Dornase 
alpha
Azithromycin Hypertonic 
saline
Airway 
clearance
Combined 
nebulized 
medicationsa
Enzymes Vitamins
eakin et al27
MPR, %b,c 65 71 76 49 NA NA NA NA
Modi et al24,d
Parent self-report, mean (SD) % 85.0 (33.7) 90.4 (25.9) NA NA 74.4 (35.3) 82.4 (31.6) 89.5 (21.7) 88.4 (27.6)
Child self-report, mean (SD) % 83.3 (25.8) 77.8 (44.1) 66.9 (30.2) 80.0 (36.9) 90.0 (25.5) 93.8 (17.1)
Daily phone diary, mean (SD) % 36.1 (35.6) 56.7 (45.8) 51.1 (40.2) 47.6 (41.0) 27.4 (22.9) 22.2 (34.2)
Notes: aincluded dornase alpha, inhaled tobramycin, albuterol; badherence rates were presented graphically only; cthere were no statistically significant differences in MPRs 
among the different medications; ddifferences in adherence rates among different medications were not evaluated statistically.
Abbreviations: MPR, medication possession ratio; NA, not applicable; SD, standard deviation.
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satisfaction, treatment burden (ie, adverse events and taste), 
and time of drug administration (ie, morning vs evening 
inhalation).21,26,28 McNamara et al28 found that treatment 
adherence was better in those patients who were younger 
than 12 years of age (,12 years of age: 71% vs $12 years 
of age: 50%). A reasonable explanation may be the pres-
ence of parental supervision in this age group. This result 
is similar to the findings of Modi et al,24 who reported that 
parental supervision of CF medical treatments can improve 
children’s treatment adherence. Furthermore, preadolescents 
and adolescents who spent more of their treatment time super-
vised by mothers had better adherence. Interestingly, Eakin 
et al27 could not identify any relationships between age and 
treatment adherence. According to the findings of Regnault 
et al,21 patient satisfaction with inhalation AB therapy was 
linked to patient adherence, and side effects seemed to be 
the key drivers of patients’ behavior regarding their inhaled 
ABs in CF. Patients’ self-perception about the efficacy of 
the drug,30 clinical response,30 cumulative toxicity,30 drug 
intolerance,26 treatment burden, and the time and frequency 
of administration24 could determine adherence to therapy. 
McNamara et al28 found that evening adherence (75%) was 
significantly better than morning adherence (58%) to inhaled 
colistimethate.28 A possible explanation of this phenomenon 
could be that children have to wake up early in the morning 
for complete airway clearance, chest physiotherapy, and inha-
lation before going to school. Unpleasant taste of the inhaled 
AB, delay in the improvement of lung function (FEV
1
 [forced 
expiratory volume in 1 second]), and respiratory symptoms 
may also lead to nonadherence.20,26,31 Furthermore, adherence 
to a novel medication may be better than to an older one.20
Real-world studies enable better understanding of the 
predictors of nonadherence from patients’ viewpoint com-
pared with RCTs. However, since measuring adherence to 
inhaled ABs as a phenomenon is relatively new, many of 
its potential predictors have not yet been evaluated, such as 
relationship between treatment adherence and health-related 
quality of life, relationship between clinical parameters (eg, 
FEV
1
) and adherence, or direct comparison of adherence 
between various type of inhaled ABs in CF.
Consequences of nonadherence
In RCTs, high adherence was observed between artificial con-
ditions compared to real-world studies. Therefore this analy-
sis made conclusions about consequences of nonadherence 
on the basis of results published by real-world studies.23–29 
Most studies concentrated on the level of adherence, on the 
identification of nonadherence, and on how adherence can 
be improved. However, only few (n=4) researches dealt with 
the consequences.23,26,27,29 Further studies are needed to under-
stand the clinical consequences of nonadherence in CF.
Generally, the examination of financial impact, not the 
clinical impact, of poor adherence dominated in the reviewed 
articles. However, it was difficult to clarify the real effect of 
nonadherence on clinical outcomes because of the natural 
progression of the disease. There are many factors (eg, micro-
biological agents and CF-related complications), not only 
treatment adherence, in CF that may have an impact on the 
progression of the disease. Our analysis suggests that better 
adherence to inhaled ABs in patients with CF is significantly 
associated with decreased health care utilization, median 
outpatient costs, excluding drug costs, and decreased risk 
of hospitalization.26,29 Moreover, reductions in CF-related 
hospitalizations translated to significant reductions in CF-
related inpatient costs. That could mean that low-adherence 
users may have more frequent pulmonary exacerbations and 
CF-related complications.29 However, Eakin et al27 found 
that adherence to inhaled tobramycin was not significantly 
associated with the occurrence of pulmonary exacerbation 
and change in FEV
1
% predicted slope.
enhancing adherence
Only few of the authors of the reviewed articles devel-
oped suggestions on how adherence to inhaled ABs can 
be improved. McNamara et al28 observed that changing 
treatment regimen from twice daily to once daily signifi-
cantly improved adherence (26% vs 54%, in 1 month). In 
a real-world, prospective cohort study, Harrison et al23 
demonstrated that the use of a more rapid delivery system 
could result in increased adherence to inhaled ABs. In their 
research, TIP was associated with better adherence compared 
with TIS (Table 1).
In the recent years, some useful tools have been devel-
oped to improve medication adherence in patients with CF. 
Internet-based adherence interventions and mobile phone 
applications became more and more popular.32 Besides 
telemedical patient management, it still seems important to 
improve patient education programs to provide home service 
programs in collaboration with social workers. However, 
the most important issue is to recognize the necessity of 
routine adherence monitoring during CF care. It is also 
important that physicians do not expect adherence to be the 
sole responsibility of patients, because improving treatment 
adherence is teamwork. Clinicians should understand their 
patients’ problems in relation to side effects or with time 
of administration and help patients to choose an inhaled 
AB that is the best for the patient. If adherence is routinely 
monitored and results are discussed openly with patients, 
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then treatment regimens can be individualized for patients. 
This kind of interaction can result in sustainable levels of 
adherence during the CF care.
Limitations
The findings of this systematic review should be considered 
in light of the following limitations. The current systematic 
literature review involved searching only studies that were 
published in English and indexed in the selected databases; 
unpublished material and studies from other resources were 
precluded. The major limitation of the analysis is that because 
of the paucity of studies, small sample sizes, and diverse defi-
nitions of adherence, adherence measurement method results 
differ vastly, and it is difficult to make any generalizing 
statements regarding the general predictors of nonadherence. 
As a further effort, we screened the references of the included 
articles for additional eligible studies. STROBE checklist was 
developed for the quality assessment of observational studies. 
Specific issues related to research using routinely collected 
data are not addressed in STROBE; nevertheless, we also 
used this checklist for quality assessment of those studies in 
which retrospective analyses were performed.
Conclusion
Different adherence definitions and measurement methods 
made it difficult to determine an overall rate for adherence 
to inhaled ABs in CF based upon the reviewed studies. 
Our analysis suggests that probably because of their highly 
controlled conditions, RCTs provide higher adherence 
rate to inhaled ABs than real-world studies. Adherence to 
inhaled ABs was found to be associated with the complexity 
of treatment, time of drug administration, age of patients, 
treatment burden (ie, adverse events and taste), and patient 
satisfaction. Further research is needed to better understand 
the predictors of adherence to inhaled ABs, which would 
be critically important to the development of effective 
adherence-enhancing interventions. Routine adherence moni-
toring, discussing the possible reasons of nonadherence with 
the patient, and changing treatment regimens on the basis of 
patient burden may optimize patient management and hence 
improve adherence in patients with CF.
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